(Press-News.org) SAN ANTONIO — Do not delay treatment of breast cancer just because a woman is pregnant, said lead researcher Sibylle Loibl, Dr. med, of the German Breast Group.
This suggestion is based on study results detailing the effects of different treatment options on the infant. Loibl presented this data at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.
"At the time we started the study in 2003, there was hardly any information on breast cancer therapy during pregnancy, but we felt there was a medical need for it," she said.
Although the incidence of pregnancy among breast cancer patients is small (about 2 to 3 percent), women are delaying childbirth until later in age, which may increase the instances of cancer cases among pregnant women, according to Loibl.
The researchers collected data from women diagnosed with breast cancer while pregnant to see how the infants fared.
From April 2003 until June 2010, they collected data from 313 women, aged 23 to 47 years old. The women had various subtypes of breast cancer, and the cancer was in various stages when diagnosed. All of the women were pregnant when they were diagnosed with cancer: 23 percent were in the first trimester, 42 percent were in the second and 36 percent were in the third trimester. Some women received various treatment regimens while the rest received chemotherapy.
Two of the infants died shortly after birth and 29 did not continue the pregnancy. Premature deliveries were more common among women who did not receive chemotherapy than among women who did receive chemotherapy. In addition, the infants of the women who received chemotherapy tended to weigh a little more than those who did not receive chemotherapy.
Infants from both groups experienced congenital problems, most of which were related to premature birth.
"We were surprised about the number of congenital malformations," Loibl said. "It is about 1 to 3 percent in the general population, but was higher in this cohort."
Although the study was primarily focused on the infant outcomes, the researchers also looked at the treatment effects on the women and found that the median overall disease-free survival of the mothers was 27 months and median overall survival was 55 months.
Based on these results Loibl said she would advise her pregnant cancer patients to "continue the pregnancy and start with a treatment as closely as possible to standard recommendations for nonpregnant women." In addition, it is critical that a multidisciplinary team in close collaboration with an obstetrician, prenatal care specialist and a neonatologist treat the pregnant woman with breast cancer.
###
Follow the AACR on Twitter @AACR, and throughout the meeting using the hash tag #SABCS.
Recordings of the teleconferences and video interviews with researchers will posted to the AACR website throughout the meeting: http://www.aacr.org/page23506.aspx.
The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 33rd annual symposium is expected to draw nearly 9,000 participants from more than 90 countries.
Unique needs and outcomes of pregnant women with breast cancer identified
2010-12-12
ELSE PRESS RELEASES FROM THIS DATE:
Novel imaging technique may reduce lymphedema in breast cancer patients
2010-12-12
SAN ANTONIO -- With guidance from a specialized scan, radiation oncologists at Mayo Clinic (http://www.mayoclinic.org/) were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.
VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Andrea Cheville and other researchers presenting at San Antonio Breast Cancer Symposium, are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2010/12/06/lymphedema-study/). These materials also ...
Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say
2010-12-12
SAN ANTONIO -- Results for testing breast tumors for HER2 (http://www.mayoclinic.com/health/breast-cancer/AN00495) proteins and genes is most often straightforward when one piece of tumor (a single tumor block) is analyzed. However, tumors can be diverse, and researchers at Mayo Clinic (http://www.mayoclinic.org/) found that HER2 results can vary in up to 10 percent of patients when several tumor blocks are analyzed.
This could have significant implications for patient treatment, say the researchers, who are presenting their findings at the 33rd Annual CTRC-AACR San ...
Higher co-payments increase chance of early discontinuation of breast cancer therapy
2010-12-12
A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer.
Dawn L. Hershman, MD, associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, will be presenting detailed study results at The 33rd CTRC-AACR San Antonio Breast Cancer Symposium, a comprehensive scientific meeting ...
Depression drug may relieve pain from breast cancer treatment, U-M study finds
2010-12-12
ANN ARBOR, Mich. — A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.
The women in the study were taking aromatase inhibitors, a type of drug designed to block the production of estrogen, which fuels some breast cancers. About half of women taking these drugs experience aches and pains in their joints and muscles that cannot be adequately relieved by over-the-counter painkillers. Up to 20 ...
Ubiquitous sugar molecule could be key to repairing deep wound without scarring
2010-12-12
Blocking fragments of the sugar molecule hyaluronan that triggers inflammation could be the key to robust healing and less scarring in deep wounds, Canadian researchers reported at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia.
In laboratory rats, the small peptide, named 15-1, which blocks fragments of the ubiquitous sugar molecule, hyaluronan, promoted wound healing, minimized scarring and forged stronger new tissue.
These effects did not occur in the untreated animals in the study, according to Cornelia Tölg, Ph.D., of the London (Ontario) ...
Pomegranate juice components inhibit cancer cell migration; in vivo testing planned
2010-12-12
Researchers at the University of California, Riverside (UCR), have identified components in pomegranate juice that seem to inhibit the movement of cancer cells and weaken their attraction to a chemical signal that has been shown to promote the metastasis of prostate cancer to the bone, according to a presentation today at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia.
The researchers in the UCR laboratory of Manuela Martins-Green, Ph.D., plan additional testing in an in vivo model for prostate cancer to determine dose-dependent effects and ...
Human spermatogonial stem cells become insulin-secreting pancreatic cells in lab
2010-12-12
Insulin-secreting pancreatic islet cells have been generated from human spermatogonial stem cells (SSCs) directly isolated from human testicular tissue, researchers reported today at the American Association of Cell Biology 50th Annual Meeting in Philadelphia.
When grafted into diabetic mice that lacked a transplant-rejecting immune system, the bioengineered cells functioned much like somatic β-islet cells, the Georgetown University (GU) Medical Center researchers said.
By decreasing the animals' blood glucose levels, the human-derived islet cells demonstrated ...
'Grow your own transplant' may be possible for men with type 1 diabetes
2010-12-12
PHILADELPHIA – Men with type 1 diabetes may be able to grow their own insulin-producing cells from their testicular tissue, say Georgetown University Medical Center (GUMC) researchers who presented their findings today at the American Society of Cell Biology 50th annual meeting in Philadelphia.
Their laboratory and animal study is a proof of principle that human spermatogonial stem cells (SSCs) extracted from testicular tissue can morph into insulin-secreting beta islet cells normally found in the pancreas. And the researchers say they accomplished this feat without use ...
Canadian scientists identify a spontaneously chain-reacting molecule
2010-12-12
In the burgeoning field of nano-science there are now many ways of 'writing' molecular-scale messages on a surface, one molecule at a time. The trouble is that writing a molecule at a time takes a very long time.
"It is much better if the molecules can be persuaded to gather together and imprint an entire pattern simultaneously, by themselves. One such pattern is an indefinitely long line, which can then provide the basis for the ultimately thin molecular 'wire' required for nano-circuitry," says John Polanyi of the University of Toronto's Department of Chemistry, co- ...
Genetic variants linked to increased risk of common gynecological disease
2010-12-12
Research published today identifies two genetic variants that increase the risk of developing endometriosis, a common gynaecological disease. The study provides clues to the origin of this often very painful condition, which has a significant impact on the quality of life of sufferers.
Details of the research, carried out at the Wellcome Trust Centre for Human Genetics and the Nuffield Department of Obstetrics & Gynaecology, University of Oxford; the Queensland Institute of Medical Research, Australia, and Brigham; and Women's Hospital and Harvard Medical School, Boston, ...